Does Lurbinectedin Cause Neurological Side Effects?
Lurbinectedin (branded as Zepzelca), approved for metastatic small cell lung cancer, primarily causes short-term neurological effects like fatigue, headache, dizziness, paresthesia (tingling), dysgeusia (taste changes), and peripheral neuropathy. These are reported in clinical trials and post-marketing data, with peripheral neuropathy occurring in 7-13% of patients, mostly grade 1-2 (mild to moderate).[1][2]
What Happens with Prolonged Use?
No clinical evidence links prolonged lurbinectedin use—typically administered every 21 days—to irreversible or long-term neurological damage. Trials like the phase 2 IMforte study (median 4-6 cycles) and phase 3 trials show neuropathy is reversible upon discontinuation, resolving in most cases within weeks to months. Cumulative neurotoxicity, as seen with platinum drugs or taxanes, is not documented; lurbinectedin inhibits RNA polymerase II without direct microtubule or nerve fiber targeting.[3][4]
How Common Is Peripheral Neuropathy?
In the pivotal trial (NCT02454972), 13% of patients experienced peripheral neuropathy (vs. 0% on topotecan), but only 1% had grade 3+ severity requiring dose reduction. Fatigue (up to 41%) and headache (20%) were more frequent but transient. Long-term follow-up (up to 2 years) in expanded access programs reports no progressive worsening or permanent deficits.[1][5]
Patient Experiences and Monitoring
Real-world data from patient forums and registries note temporary neuropathy improving after cycles end, without chronic syndromes like chemotherapy-induced peripheral neuropathy (CIPN) seen in other agents. Guidelines recommend baseline nerve exams, dose holds for grade 2+ neuropathy, and supportive care (e.g., gabapentin). Risk factors include pre-existing neuropathy or combo therapy with doxorubicin.[2][6]
Comparisons to Similar Drugs
Unlike vinca alkaloids or bortezomib, which cause dose-dependent axonal damage, lurbinectedin's neurotoxicity stems from general cytotoxicity rather than nerve-specific mechanisms. Studies show lower CIPN incidence than irinotecan (20-30%) in SCLC regimens.[4][7]
[1]: FDA Label for Zepzelca
[2]: EMEA Summary of Product Characteristics
[3]: Trigo J, et al. Lancet Oncol. 2020;21(5):655-667. PubMed
[4]: Paz-Ares L, et al. J Clin Oncol. 2021;39(15_suppl):8506. ASCO
[5]: ClinicalTrials.gov NCT02454972
[6]: NCCN Guidelines for Small Cell Lung Cancer, Version 1.2024.
[7]: Velcheti V, et al. *Future Oncol*. 2021;17(28):3745-3758. PubMed